Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Ab­b­Vie’s ef­fort to pro­tect Hu­mi­ra’s mar­ket share is get­ting ex­pen­sive.

On Fri­day, the com­pa­ny an­nounced a 40% de­cline in the megablock­buster drug’s US sales for the first quar­ter. While it man­aged to hang on­to the vast ma­jor­i­ty of mar­ket share, Ab­b­Vie did so by of­fer­ing sub­stan­tial dis­counts to com­pete with the biosim­i­lars that have flood­ed the mar­ket.

While the drop in Hu­mi­ra sales — which made up 18.4% of Ab­b­Vie’s world­wide rev­enue in the first quar­ter — was bet­ter than Wall Street an­a­lysts had pro­ject­ed, the com­pa­ny will face far stiffer com­pe­ti­tion this quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER